Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Capecitabine (Primary) ; Telaglenastat (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 07 Jun 2023 Planned End Date changed from 1 Jan 2023 to 1 Jun 2023.
- 14 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Jan 2023.